Gapping up
In reaction to strong earnings/guidance: HTGM +34.9%, (also HTG Molecular Diagnostics enters into research collaboration with Bristol-Myers Squibb (BMY) to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types ), NVDA +7.5%, SHAK +6.5%, KMPH +5.7%, BAM +1.2%
M&A news: WGBS +65.5% (to be acquired by Takara Bio), SPHS +4.2% (engages financial advisors to assist with evaluation of strategic alternatives)
Select Chinese ADRs showing strength following recent weakness this week: MOMO +7.7%, YY +5.2%, DANG +4.7%, QIHU +3%
Select metals/mining stocks trading higher: HMY +5.3%, SBGL +3.4%, PAAS +3.2%, KGC +3.1%, AU +3.1%, GFI +2.7%, ABX +1.8%, GDX +1.4%, GG +1.4%, SSRI +1.4%, NEM +1.3%, IAG +1.1%, BBL +1%
Other news: CLBS +12.9% (confirms it was granted orphan designation by the FDA for its compound for the treatment of type 1 diabetes mellitus with residual beta cell function), SJI +2.9% (upsizes offering by 500K shares and prices 7 mln shares of common stock at $26.25), FEYE +0.8% (incoming President Travis Reese purchases 35k shares in the open market), ADRO +0.6% (Aduro Biotech receives $35 mln milestone payment from Novartis)
Analyst comments: AGN +0.7% (added to Conviction Buy List at Goldman), NOK +0.6% (upgraded to Buy from Neutral at BofA/Merrill)
In reaction to strong earnings/guidance: HTGM +34.9%, (also HTG Molecular Diagnostics enters into research collaboration with Bristol-Myers Squibb (BMY) to evaluate the potential for immuno-oncology molecular profiling in multiple tumor types ), NVDA +7.5%, SHAK +6.5%, KMPH +5.7%, BAM +1.2%
M&A news: WGBS +65.5% (to be acquired by Takara Bio), SPHS +4.2% (engages financial advisors to assist with evaluation of strategic alternatives)
Select Chinese ADRs showing strength following recent weakness this week: MOMO +7.7%, YY +5.2%, DANG +4.7%, QIHU +3%
Select metals/mining stocks trading higher: HMY +5.3%, SBGL +3.4%, PAAS +3.2%, KGC +3.1%, AU +3.1%, GFI +2.7%, ABX +1.8%, GDX +1.4%, GG +1.4%, SSRI +1.4%, NEM +1.3%, IAG +1.1%, BBL +1%
Other news: CLBS +12.9% (confirms it was granted orphan designation by the FDA for its compound for the treatment of type 1 diabetes mellitus with residual beta cell function), SJI +2.9% (upsizes offering by 500K shares and prices 7 mln shares of common stock at $26.25), FEYE +0.8% (incoming President Travis Reese purchases 35k shares in the open market), ADRO +0.6% (Aduro Biotech receives $35 mln milestone payment from Novartis)
Analyst comments: AGN +0.7% (added to Conviction Buy List at Goldman), NOK +0.6% (upgraded to Buy from Neutral at BofA/Merrill)